More than just a simple rise, the pharmaceutical company's stock has been re-evaluated due to a growth narrative that ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

If ACD680 were to reach the market, it would deepen Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla.

Eli Lilly (NYSE: LLY) has been a major winner from this boom. The drugmaker's Zepbound is one of the best-selling ...

Eli Lilly LLY announced that the FDA has approved a new maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz) for adults ...

Eli Lilly and Boehringer Ingelheim are cutting back on planned investments in Germany in response to a new government ...

Foundayo was incredibly effective at lowering A1C, which is a metric doctors use to measure average blood sugar levels over a ...

Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness. The deal is the latest from Lilly, which ...

Eli Lilly (NYSE: LLY) and Vertex Pharmaceuticals (NASDAQ: VRTX) have several things in common. Both are among the more prominent drugmakers in the world, and both have delivered market-beating returns ...

FRANKFURT, June 9 (Reuters) - The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned ...

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech ...